Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HK-660S in Primary Sclerosing Cholangitis
NCT06975150Phase 2Not yet recruiting
- Sponsor
- Curome Biosciences
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lapachone in Primary Sclerosing Cholangitis (PSC), sponsored by Curome Biosciences. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
lapachone
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06975150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975150.